By Mill Chart
Last update: Dec 21, 2023
EXELIXIS INC (NASDAQ:EXEL) has caught the eye of our stock screener as an affordable growth stock. NASDAQ:EXEL is displaying robust growth metrics and also excels in terms of profitability, solvency, and liquidity. Additionally, it appears to be reasonably priced. Let's delve into the details.
ChartMill employs its own Growth Rating system for all stocks. This score, ranging from 0 to 10, is derived by evaluating different growth factors, such as EPS and revenue growth, taking into account both past performance and future projections. NASDAQ:EXEL has earned a 7 for growth:
ChartMill assigns a Valuation Rating to each stock, ranging from 0 to 10. This rating is calculated by analyzing different valuation elements, such as price to earnings and free cash flow, both in absolute terms and relative to the market and industry. In the case of NASDAQ:EXEL, the assigned 5 reflects its valuation:
A critical element of ChartMill's stock evaluation is the Health Rating, which spans from 0 to 10. This rating considers multiple health factors, including liquidity and solvency, both in absolute terms and relative to industry peers. NASDAQ:EXEL has received a 7 out of 10:
ChartMill assigns a proprietary Profitability Rating to each stock. The score is computed by evaluating various profitability ratios and margins and ranges from 0 to 10. NASDAQ:EXEL was assigned a score of 8 for profitability:
Our Affordable Growth screener lists more Affordable Growth stocks and is updated daily.
Check the latest full fundamental report of EXEL for a complete fundamental analysis.
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
EXELIXIS INC
NASDAQ:EXEL (4/23/2024, 7:00:01 PM)
After market: 23.683 +0.39 (+1.69%)23.29
+0.42 (+1.84%)
Some of the best opportunities can be found in dips in some of the top biotech stocks to buy. In fact, here are three.
Phenomenal deals can still be found, even with the Nasdaq Composite climbing to a new all-time high.
These stocks are worth buying in most months of the year.
With excellent financial health and great prospects, these three biotech stocks just may be the the next stars of the sector.
The growth-driven Nasdaq Composite has entered a new bull market, but plain-as-day deals can still be found.
You don't need to be a millionaire to get started. Investing on a budget can work, too.
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NYSE:PFE),(NASDAQ:BTAI),(NYSE:BMY) EQNX::TICKER_END
The best biotech stocks to buy offer consistent growth opportunities and resist the influence of singular drug successes.